NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Breathing in cancer drugs: new trial aims to boost lung cancer surgery success
Disease control Not yet recruitingThis study is testing if adding an inhaled drug called azacytidine to standard pre-surgery treatment can better shrink early-stage lung cancer tumors. The goal is to find the safest dose of the inhaled drug and see if it helps eliminate more cancer cells before surgery. About 60 …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for lung cancer patients when disease morphs into more aggressive form
Disease control Not yet recruitingThis study is testing a new combination of drugs for people with a specific type of lung cancer. It's for patients whose non-small cell lung cancer has changed into a more aggressive small-cell type after their first treatment stopped working. The trial will see if adding a new t…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Hunan Province Tumor Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo tested in fight against advanced cancers
Disease control Not yet recruitingThis study is testing an experimental drug called QLS5132, given by IV in combination with other cancer therapies, for people with advanced solid tumors like lung, stomach, ovarian, and endometrial cancer. The main goals are to find a safe and effective dose and to see how well t…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Ancient medicine meets modern tech in lung cancer fight
Disease control Not yet recruitingThis study is testing whether adding a traditional Chinese herbal medicine called Huaier granules to a standard microwave ablation treatment works better for people with early-stage lung cancer who cannot have surgery. About 180 participants will be randomly assigned to receive e…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Xin Ye • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for tough cancers: experimental drug targets key mutation
Disease control Not yet recruitingThis study is testing a new oral drug called BPI-572270 for people with advanced cancers that have specific RAS genetic mutations. Researchers want to find the safest and most effective dose, and see if it helps control cancers like lung, colorectal, and pancreatic cancer that ha…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New drug challenges standard treatment in major lung cancer trial
Disease control Not yet recruitingThis study is testing whether a new drug called pumitamig works better than the current standard treatment (durvalumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The trial will involve 850 participants whose cancer hasn't progressed a…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Brain vs. body: new trial tests stronger drug dose against Drug-Chemo combo for tough lung cancer
Disease control Not yet recruitingThis study aims to find the better first treatment for people with a specific type of lung cancer (EGFR-mutated NSCLC) that has spread to the brain. It will compare a higher dose of the targeted drug furmonertinib taken alone against a lower dose of the same drug combined with tw…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Looking back: can a drug combo help more lung cancer patients before surgery?
Disease control Not yet recruitingThis study looks back at the medical records of 100 patients in Taiwan with operable non-small cell lung cancer. It aims to see how well and how safely the drug nivolumab works when given with standard chemotherapy before surgery. The goal is to understand if this combination hel…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Ono Pharmaceutical Co. Ltd • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New drug challenges standard in major lung cancer trial
Disease control Not yet recruitingThis study aims to see if a new drug called pumitamig works better than the current standard treatment (pembrolizumab) for people with advanced non-small cell lung cancer. It will involve 750 adults who have not yet received treatment for their advanced cancer and whose tumors ha…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Smartwatch-Guided recovery aims to help lung cancer patients breathe easier after surgery
Disease control Not yet recruitingThis study is testing a new digital recovery program for people having surgery for lung cancer. It uses smartwatches and a phone app to guide patients through exercises and track their health before and after surgery. Researchers want to see if this tech-supported approach helps …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: West China Hospital • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC
-
New hope for advanced lung cancer patients in clinical trial
Disease control Not yet recruitingThis study is testing a new drug called JSKN033 for adults with advanced non-small cell lung cancer (NSCLC) that cannot be cured by surgery or radiation. The main goals are to see how safe the drug is and if it can shrink or control the cancer. The study will also measure how the…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Mar 09, 2026 14:27 UTC
-
Simple blood test could tell doctors which cancer patients will respond to immunotherapy
Diagnosis Not yet recruitingThis study aims to develop a blood test that predicts whether cancer patients will benefit from immunotherapy drugs. Researchers will analyze blood samples from 600 patients with lung cancer, melanoma, breast cancer, kidney cancer, or head/neck cancer before they start treatment.…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: OncoHost Ltd. • Aim: Diagnosis
Last updated Mar 31, 2026 12:11 UTC
-
Can a workout plan help patients breathe easier after lung cancer surgery?
Symptom relief Not yet recruitingThis small pilot study aims to see if a supervised 6-month athletic training program can help patients recover after surgery for non-small cell lung cancer. The study will enroll 10 patients who have had surgery and are in otherwise good health. Researchers will measure if the ex…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Symptom relief
Last updated Mar 30, 2026 14:31 UTC
-
Can ancient chinese medicine predict modern cancer drug success?
Knowledge-focused Not yet recruitingThis study aims to understand if a patient's Traditional Chinese Medicine (TCM) body pattern relates to how well their targeted lung cancer drugs work. Researchers will observe 3000 patients with a specific lung cancer mutation who are taking EGFR-TKI drugs as part of their stand…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC